Lantheus
LNTH
Hutchmed (China)
HCM
Workday
WDAY
DexCom
DXCM
Halozyme Therapeutics
HALO
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 395.64%222.07M | 616.25%90M | 1,029.79%71.62M | 152.51%28.39M | 686.85%32.06M | 20.11%-75.11M | 51.22%-17.43M | 76.74%-7.7M | -79.80%-54.05M | -16.85%4.08M |
Net income from continuing operations | -433.20%-484.28M | 283.27%71.04M | 504.35%29.85M | 75.43%-10.1M | -844.81%-575.07M | 42.72%-90.82M | 183.39%18.53M | 83.70%-7.38M | 26.24%-41.11M | -72.49%-60.87M |
Depreciation and amortization | 14.17%15.64M | 10.81%4.16M | 20.71%3.97M | 13.52%3.77M | 12.13%3.74M | 71.28%13.7M | 11.33%3.76M | 18.57%3.29M | 233.77%3.32M | 288.59%3.34M |
Other non cash items | -100.65%-77K | -105.78%-79K | -188.56%-3.21M | -58.60%1.48M | -47.09%1.74M | -18.68%11.84M | -61.05%1.37M | -41.01%3.63M | 45.10%3.57M | 34.03%3.29M |
Change In working capital | -124.96%-67.47M | -21.91%-58.72M | -136.89%-21.35M | 17.31%-19.67M | -36.69%32.27M | -197.53%-29.99M | -47.98%-48.16M | -13.99%-9.01M | -578.53%-23.78M | 100.62%50.97M |
-Change in receivables | -95.58%-104.28M | -24.27%-65.37M | -72.10%-44.11M | -180.69%-24.79M | -11.14%29.99M | -76.37%-53.32M | -47.06%-52.6M | -26.50%-25.63M | -396.71%-8.83M | 47.87%33.75M |
-Change in prepaid assets | -602.45%-19.49M | -534.38%-7.72M | 561.12%8.42M | -440.76%-6.27M | -1,274.70%-13.91M | 302.93%3.88M | -62.93%1.78M | -72.33%1.27M | -56.58%1.84M | 93.49%-1.01M |
-Change in payables and accrued expense | 132.85%58.69M | 344.29%14.08M | -10.24%15.72M | 183.52%12.18M | -12.47%16.73M | -22.17%25.21M | 308.25%3.17M | 38.42%17.51M | -3,726.51%-14.58M | -1.20%19.11M |
-Change in other working capital | 58.37%-2.4M | 157.28%291K | 36.44%-1.38M | 64.72%-780K | 39.15%-530K | 44.23%-5.76M | 78.37%-508K | 55.75%-2.17M | -18.62%-2.21M | 28.19%-871K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 395.64%222.07M | 616.25%90M | 1,029.79%71.62M | 152.51%28.39M | 686.85%32.06M | 20.11%-75.11M | 51.22%-17.43M | 76.74%-7.7M | -79.80%-54.05M | -16.85%4.08M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -1,167.27%-440.69M | -134.06%-43.1M | 208.47%7.94M | -1,529.31%-519.64M | 28.18%114.1M | 105.13%41.29M | -42.92%-18.41M | 103.71%2.58M | 52.33%-31.89M | 113.59%89.02M |
Net PPE purchase and sale | 35.75%-6.25M | 81.70%-842K | 65.63%-1.35M | -44.82%-1.2M | -700.84%-2.85M | -56.01%-9.72M | -246.54%-4.6M | -59.42%-3.94M | 28.26%-830K | 72.17%-356K |
Net intangibles purchase and sale | --6.87M | --0 | --6.87M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Net business purchase and sale | ---17.14M | --0 | ---17.14M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Net investment purchase and sale | -932.21%-423.12M | -193.69%-40.75M | 192.86%19.08M | -1,566.69%-518.42M | 30.97%116.97M | 106.73%50.84M | -26.97%-13.87M | 113.05%6.51M | 24.31%-31.11M | 113.66%89.31M |
Net other investing changes | -709.30%-1.05M | -2,493.65%-1.51M | 16,333.33%487K | -128.57%-12K | -121.43%-15K | 368.75%172K | 200.00%63K | -123.08%-3K | --42K | --70K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -1,167.27%-440.69M | -134.06%-43.1M | 208.47%7.94M | -1,529.31%-519.64M | 28.18%114.1M | 105.13%41.29M | -42.92%-18.41M | 103.71%2.58M | 52.33%-31.89M | 113.59%89.02M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 46,898.40%379.54M | -125.96%-703K | -14,080.27%-31.62M | -2,887.72%-9.31M | 11,702.51%421.17M | 78.57%-811K | 1,047.46%2.71M | 85.56%-223K | 108.82%334K | -377.31%-3.63M |
Net common stock issuance | --600.02M | --0 | --0 | --0 | --600.02M | --0 | --0 | --0 | --0 | --0 |
Proceeds from stock option exercised by employees | 955.67%88.97M | 345.64%26.04M | 4,686.02%38M | 122.05%1.84M | 2,302.60%23.09M | 19.82%8.43M | 580.21%5.84M | 5.59%794K | -37.36%830K | -76.55%961K |
Net other financing activities | -3,249.49%-309.46M | -753.01%-26.74M | -6,745.92%-69.62M | -2,148.79%-11.15M | -4,298.61%-201.94M | 14.60%-9.24M | -403.21%-3.14M | 55.71%-1.02M | 90.29%-496K | -64.61%-4.59M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 46,898.40%379.54M | -125.96%-703K | -14,080.27%-31.62M | -2,887.72%-9.31M | 11,702.51%421.17M | 78.57%-811K | 1,047.46%2.71M | 85.56%-223K | 108.82%334K | -377.31%-3.63M |
Net cash flow | ||||||||||
Beginning cash position | -7.95%401.23M | 18.78%515.95M | 6.43%468M | 84.37%968.57M | -7.95%401.23M | -67.42%435.86M | -10.30%434.36M | -25.26%439.72M | -23.76%525.33M | -67.42%435.86M |
Current changes in cash | 564.62%160.92M | 239.41%46.2M | 995.96%47.94M | -484.69%-500.56M | 534.13%567.34M | 96.16%-34.63M | 31.51%-33.14M | 94.86%-5.35M | 15.03%-85.61M | 113.79%89.47M |
End cash Position | 40.11%562.14M | 40.11%562.14M | 18.78%515.95M | 6.43%468M | 84.37%968.57M | -7.95%401.23M | -7.95%401.23M | -10.30%434.36M | -25.26%439.72M | -23.76%525.33M |
Free cash flow | 354.39%215.82M | 504.61%89.16M | 703.74%70.27M | 149.53%27.18M | 685.51%29.21M | 15.38%-84.84M | 40.55%-22.04M | 67.30%-11.64M | -75.79%-54.88M | 2.68%3.72M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |